Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report)’s stock price traded up 9.5% during trading on Monday after Piper Sandler raised their price target on the stock from $28.00 to $42.00. Piper Sandler currently has an overweight rating on the stock. Scholar Rock traded as high as $29.18 and last traded at $29.02. 1,205,993 shares changed hands during trading, an increase of 7% from the average session volume of 1,130,772 shares. The stock had previously closed at $26.51.
SRRK has been the subject of a number of other reports. Wedbush increased their price target on shares of Scholar Rock from $27.00 to $37.00 and gave the stock an “outperform” rating in a research note on Monday, October 7th. BMO Capital Markets increased their price target on shares of Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a research note on Friday, October 11th. HC Wainwright raised their target price on shares of Scholar Rock from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Finally, JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $31.63.
View Our Latest Report on SRRK
Insider Activity at Scholar Rock
Institutional Investors Weigh In On Scholar Rock
A number of large investors have recently added to or reduced their stakes in the stock. American International Group Inc. grew its position in Scholar Rock by 3.0% in the 1st quarter. American International Group Inc. now owns 28,407 shares of the company’s stock worth $505,000 after purchasing an additional 834 shares during the period. Jennison Associates LLC grew its position in Scholar Rock by 1.0% in the 1st quarter. Jennison Associates LLC now owns 138,458 shares of the company’s stock worth $2,459,000 after purchasing an additional 1,409 shares during the period. Rice Hall James & Associates LLC grew its position in shares of Scholar Rock by 3.6% during the 2nd quarter. Rice Hall James & Associates LLC now owns 46,000 shares of the company’s stock valued at $383,000 after acquiring an additional 1,594 shares during the period. ProShare Advisors LLC grew its position in shares of Scholar Rock by 11.7% during the 1st quarter. ProShare Advisors LLC now owns 15,412 shares of the company’s stock valued at $274,000 after acquiring an additional 1,620 shares during the period. Finally, ClariVest Asset Management LLC grew its position in shares of Scholar Rock by 3.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 59,640 shares of the company’s stock valued at $497,000 after acquiring an additional 1,718 shares during the period. Institutional investors own 91.08% of the company’s stock.
Scholar Rock Stock Performance
The business’s 50-day moving average price is $11.51 and its 200-day moving average price is $11.26. The company has a debt-to-equity ratio of 0.36, a quick ratio of 6.04 and a current ratio of 6.04. The stock has a market cap of $2.28 billion, a P/E ratio of -13.66 and a beta of 0.82.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.01. During the same quarter in the prior year, the company posted ($0.47) EPS. As a group, sell-side analysts expect that Scholar Rock Holding Co. will post -2.38 earnings per share for the current fiscal year.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Featured Stories
- Five stocks we like better than Scholar Rock
- Top Biotech Stocks: Exploring Innovation Opportunities
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.